Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography. Case report

European Journal of Gynaecological Oncology

Volumn 23, Issue 1, 2002, Pages 25-28

  Renard, F ^a   Vosse, M ^a   Scagnol, I ^a   Verhest, A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Pap smear; Sensitivity; Surveillance strategy; Tamoxifen; Transvaginal ultrasonography; Uterine neoplasms

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CURETTAGE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; FEMALE; HUMAN; HYSTEROSCOPY; PAPANICOLAOU TEST; RADICAL HYSTERECTOMY; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CONIZATION;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; ENDOMETRIAL NEOPLASMS; ENDOSONOGRAPHY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAMOXIFEN; VAGINA; VAGINAL SMEARS;

EID: 0036181730     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
3. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer
4. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
5. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients
6. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
7. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
8. Hysteroscopic follow-up during tamoxifen treatment
9. Surveillance for endometrial cancer in women receiving tamoxifen
10. Tamoxifen and endometrial pathologies: A prospective study
11. The effect of tamoxifen on the endometrium
12. Benign and hyperplastic endometrial changes associated with tamoxifen use
13. Tamoxifen and endometrial cancer
14. Gynaecology. Hormonal interventions and cancer risk
15. The Barakat article reviewed
16. Surveillance of the endometrium in tamoxifen treated women
17. Uterine side effects of tamoxifen: A need for systematic pretreatment screening
18. Endometrial thickness in tamoxifen-treated patients: An independent predictor of endometrial disease
19. Resume trials, add endometrial sampling
20. Should tamoxifen users be screened for endometrial lesions?
21. Tamoxifen: The need for a monitoring protocol
22. Gynecologic effects of tamoxifen and the association with endometrial carcinoma
23. Endometrial disorders in 406 breast cancer patients on tamoxifen: Advocating for a low aggressive monitoring
24. Classification of endometrial cells on cervical cytology
25. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors
26. Significance of endometrial cells in cervicovaginal smears
27. The validity of Pap smear parameters as predictors of endometrial pathology in menopausal women
28. Effects of tamoxifen on cervicovaginal smears from patients with breast cancer
29. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features
30. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients